ATE412771T1 - Verfahren zur modulation der tubulindeacetylase- aktivität - Google Patents

Verfahren zur modulation der tubulindeacetylase- aktivität

Info

Publication number
ATE412771T1
ATE412771T1 AT03726921T AT03726921T ATE412771T1 AT E412771 T1 ATE412771 T1 AT E412771T1 AT 03726921 T AT03726921 T AT 03726921T AT 03726921 T AT03726921 T AT 03726921T AT E412771 T1 ATE412771 T1 AT E412771T1
Authority
AT
Austria
Prior art keywords
deacetylase activity
tubulin deacetylase
modulating
modulating tubulin
ribavirin
Prior art date
Application number
AT03726921T
Other languages
English (en)
Inventor
Eric Verdin
Brian J North
Scott Ulrich
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE412771T1 publication Critical patent/ATE412771T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03726921T 2002-05-20 2003-05-20 Verfahren zur modulation der tubulindeacetylase- aktivität ATE412771T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38221802P 2002-05-20 2002-05-20

Publications (1)

Publication Number Publication Date
ATE412771T1 true ATE412771T1 (de) 2008-11-15

Family

ID=29584377

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726921T ATE412771T1 (de) 2002-05-20 2003-05-20 Verfahren zur modulation der tubulindeacetylase- aktivität

Country Status (8)

Country Link
US (2) US7351542B2 (de)
EP (2) EP1514105B1 (de)
AT (1) ATE412771T1 (de)
AU (1) AU2003229329B2 (de)
CA (1) CA2485988C (de)
DE (1) DE60324427D1 (de)
ES (1) ES2318131T3 (de)
WO (1) WO2003099210A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE497015T1 (de) 2002-05-23 2011-02-15 Univ California Verfahren zum auswählen von modulatoren der mitochondrialen nad-abhängigen deacetylase, sirt3
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
AU2004312072B2 (en) * 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007529422A (ja) * 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
US20050256181A1 (en) * 2004-01-29 2005-11-17 Elixir Pharmaceuticals, Inc. Treating a viral disorder
PT1720540E (pt) 2004-02-18 2008-09-10 Gpc Biotech Ag Métodos de tratamento de tumores resistentes ou refractários
CA2584493A1 (en) 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
EP1824831A2 (de) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
AU2006218407B2 (en) * 2005-03-03 2012-11-15 Sirtris Pharmaceuticals, Inc. Fluorescence polarization assays for acetyltransferase/deacetylase activity
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
ES2389111T3 (es) * 2005-12-02 2012-10-23 Sirtris Pharmaceuticals, Inc. Ensayos de espectrometría de masas para la actividad acetiltransferasa/desacetilasa
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8518635B2 (en) * 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
GB0909912D0 (en) 2009-06-09 2009-07-22 Univ Dundee Compounds
US20110190305A1 (en) 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
US9290791B2 (en) 2010-05-18 2016-03-22 Cornell University Reagents and methods for sirtuin capture
JP5947623B2 (ja) * 2012-06-04 2016-07-06 インフォコム株式会社 抗がん剤の効果増強剤
FR3086493B1 (fr) * 2018-09-20 2020-08-28 Renault Sas Procede de reattribution d’un serveur peripherique de traitement de donnees
WO2024158914A1 (en) * 2023-01-24 2024-08-02 Beth Israel Deaconess Medical Center, Inc. Optical sensor probes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8800276D0 (en) 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
TW197439B (de) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
AU7623194A (en) 1993-09-03 1995-03-22 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
AU706417B2 (en) 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
AU2253397A (en) 1996-01-23 1997-08-20 Affymetrix, Inc. Nucleic acid analysis techniques
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
WO1998022451A1 (fr) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Derives taxol
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
WO1998058927A1 (en) 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
EP1529115A4 (de) * 2001-07-06 2005-08-24 Elixir Pharmaceuticals Inc Sir2-aktivität
AU2002362030A1 (en) * 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity

Also Published As

Publication number Publication date
CA2485988A1 (en) 2003-12-04
WO2003099210A2 (en) 2003-12-04
WO2003099210A3 (en) 2004-03-18
US20090005328A1 (en) 2009-01-01
CA2485988C (en) 2013-12-24
EP1514105B1 (de) 2008-10-29
EP1982720A1 (de) 2008-10-22
US7351542B2 (en) 2008-04-01
US20040028607A1 (en) 2004-02-12
EP1514105A2 (de) 2005-03-16
DE60324427D1 (de) 2008-12-11
AU2003229329A1 (en) 2003-12-12
ES2318131T3 (es) 2009-05-01
AU2003229329B2 (en) 2009-08-06
US7884081B2 (en) 2011-02-08
EP1514105A4 (de) 2006-05-17

Similar Documents

Publication Publication Date Title
ATE412771T1 (de) Verfahren zur modulation der tubulindeacetylase- aktivität
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE531365T1 (de) Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2004006906A3 (en) Methods for the treatment of neoplasms
PT1083879E (pt) Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
UA86344C2 (ru) Способ лечения сосудистых заболеваний
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
RS20050344A (en) Treatment for hemorrhagic shock
DE602004025726D1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
WO2002084298A3 (en) Medicaments which are modulators of hm74 and/or hm74a activity
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
EP1011672A4 (de) Verbindungen mit analgetischem effekt und zusammenstellungen die diese enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties